Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | GRK6 | P43250 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1855642 | 1.00 | MAPT (0.42) | MAPTKAT2BGRK6KDM4EGAA | |
| SCHEMBL4395379 | 0.81 | KAT2B (0.47) | MAPTKAT2BGRK6KDM4ECYP3A4 | |
| SCHEMBL4395374 | 0.81 | KAT2B (0.47) | MAPTKAT2BGRK6KDM4ECYP3A4 | |
| SCHEMBL1856142 | 0.81 | GUCY1A1 (0.36) | MAPTKDM4EGAACYP3A4ALDH1A1 | |
| SCHEMBL1855648 | 0.79 | MAPT (0.50) | MAPTGAAALDH1A1KMT2ANPC1 | |
| SCHEMBL1855646 | 0.79 | MAPT (0.50) | MAPTGAAALDH1A1KMT2ANPC1 | |
| SCHEMBL27756761 | 0.75 | MAPT (0.47) | MAPTKAT2BGRK6KDM4ECYP3A4 | |
| SCHEMBL27756758 | 0.73 | KAT2B (0.45) | MAPTKAT2BGRK6CYP3A4TSHR | |
| SCHEMBL18342237 | 0.71 | HCAR3 (0.39) | MAPTKAT2BKDM4ETSHRALDH1A1 | |
| SCHEMBL18342238 | 0.71 | HCAR3 (0.39) | MAPTKAT2BKDM4ETSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7939658-B2 | Enantiomeric pure beta agonists, manufacturing and use as a medicaments thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-10 | — | — | US | disclosed |
| US-7534789-B2 | Enantiomeric pure β agonists, manufacturing and use as a medicament thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-19 | — | — | US | disclosed |
| US-20070249595-A1 | Novel Enantiomeric Pure Beta Agonists, Manufacturing and Use as a Medicament Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249595-A1 | Novel Enantiomeric Pure Beta Agonists, Manufacturing and Use as a Medicament Thereof | ADRB1, ADRA1B, ADRA2B | MAPT 4006/4885KAT2B 3198/4885GRK6 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.